Gold Track worked with Ochre Bio at the early stages of their development supporting them in refining their technology-market fit, identifying clinical need, refining worldwide product strategy, investor introductions, and storytelling. In April 2024, Ochre Bio closed a $1.3B deal with Boehringer Ingelheim to treat metabolic-associated steatohepatitis (MASH).